Bexarotene and systemic disease progression in CTCL?
Dummer
Reinhard
R
Hauschild
Axel
A
Skalsky
Jeannine
J
Burg
Günter
G
Weichenthal
Michael
M
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077610:Bexarotene; D018450:Disease Progression; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D009182:Mycosis Fungoides / Q000188:drug therapy; D015203:Reproducibility of Results; D012307:Risk Factors; D012751:Sezary Syndrome / Q000188:drug therapy; D013764:Tetrahydronaphthalenes / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene